EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, INVA:

05 Sep 2025
LAST:

20.48

CHANGE:
 0.44		OPEN:
20.94		HIGH:
20.97		ASK:
10.40		VOLUME:
950.1K
CHG(%):
2.10		PREV:
20.92		LOW:
20.28		BID:
6.11		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Sep 2520.9420.9720.2820.48950.1K
04 Sep 2520.9321.1120.7920.92608.8K
03 Sep 2520.8121.0720.7520.90716.4K
02 Sep 2520.5321.1220.5320.88881.3K
29 Aug 2520.0320.4819.8720.43650.8K
28 Aug 2519.8120.0619.6020.03510.8K
27 Aug 2520.0320.2719.8019.84645.6K
26 Aug 2519.8820.0019.6819.93698.4K
25 Aug 2520.1520.3119.6619.76615.5K
22 Aug 2520.1120.3519.9620.16521.1K

COMPANY PROFILE

Name:
About:Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Sector:Healthcare
Industry:Biotechnology
Address:1350 Old Bayshore Highway, Burlingame, CA, United States, 94010
Website:https://www.inva.com
CUSIP:88338T104
CIK:0001080014
ISIN:US45781M1018
FIGI:BBG000CG9XT7
LEI:549300ACOX4QTBES6535

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:36.00
Price to Book:1.83
Price to Sales:3.49
EBITDA:206.86M
Shares:63.02M
Market Cap:1.291B

TECHNICAL INDICATORS

MA5:20.72
MA10:20.33
MA20:20.25
MA50:19.60
MA100:19.58
MA200:18.83
STO9:52.94
STO14:52.94
RSI14:43.43
WPR14:-37.93
MTM14:-0.30
ROC14:-0.01
ATR:0.52
Week High:21.12
Week Low:19.87
Month High:21.13
Month Low:17.89
Year High:22.00
Year Low:16.67
Volatility:7.57

RECENT SPLITS

Date Ratio
03 Jun 20141241-1000

RECENT DIVIDENDS

Date Amount
08 Sep 2015$0.25
10 Jun 2015$0.25
10 Mar 2015$0.25
21 Nov 2014$0.25
26 Aug 2014$0.25